Coagulation factor VIIa and tissue factor complex (FVIIa/TF complex)

The Coagulation factor VIIa and tissue factor complex, often referred to as the extrinsic tenase complex, serves as the primary physiological initiator of the blood coagulation cascade (nih.gov [1.1.1]). It is formed when circulating activated Factor VII (FVIIa) binds to its essential cofactor, Tissue Factor (TF), a transmembrane protein typically sequestered from the blood but exposed upon vascular injury (nih.gov [1.1.2]). Once assembled, the complex acts as a potent serine protease that catalyzes the conversion of Factor X to Factor Xa and Factor IX to Factor IXa, ultimately leading to a burst of thrombin generation and the formation of a stable fibrin clot (ahajournals.org [1.2.2]). Beyond its critical role in hemostasis, the TF:FVIIa complex also functions as a signaling scaffold that activates protease-activated receptor 2 (PAR2), thereby modulating cellular processes such as inflammation, angiogenesis, and tumor cell migration (nih.gov [1.1.5]). In clinical practice, recombinant FVIIa (e.g., eptacog alfa) is a vital therapeutic agent used to bypass missing factors in hemophilia patients with inhibitors, effectively promoting hemostasis at sites of injury (nih.gov [1.3.4]). Conversely, the complex is a target for anti-thrombotic and anti-cancer strategies, where inhibitors or antibody-drug conjugates like tisotumab vedotin are designed to block its procoagulant activity or disrupt its role in pathological signaling and tumor progression (patsnap.com [1.2.1]).

Other names

Extrinsic tenase complexTF:FVIIa complexFactor VIIa-Tissue Factor complexThromboplastin-Factor VIIa complexFactor III-Factor VIIa complexActivated factor VII-tissue factor complex

The complex initiates the extrinsic pathway of coagulation by activating factors X and IX (nih.gov [1.3.1]). Drugs like recombinant factor VIIa (rFVIIa) enhance this process to treat bleeding by facilitating thrombin generation on activated platelets (nih.gov [1.3.4]). Conversely, inhibitors block the complex's catalytic activity or formation to prevent thrombosis or disrupt PAR2-mediated signaling pathways involved in tumor growth and inflammation (patsnap.com [1.2.1], nih.gov [1.1.5]).